

April 11, 2019



ResMed to Report Third Quarter Fiscal 2019 Earnings on May 2, 2019

SAN DIEGO--(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.

Earnings webcast details:

- Location: <http://investor.resmed.com>
- Date: Thursday, May 2, 2019
- Time: 1:30 p.m. PT / 4:30 p.m. ET
- International: London, Thursday, May 2, 9:30 p.m.
Sydney, Friday, May 3, 6:30 a.m.

Please note that ResMed does not use outside phone lines to access the earnings call.

A replay of the earnings webcast will be accessible on ResMed's website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from May 2 until May 16 at:

- U.S.: +1 800.585.8367
- International: +1 416.621.4642
- Passcode: 3977963

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190411005679/en/>

For media:

Jayne Rubenstein

+1 858.836.6798

news@resmed.com

For investors:

Amy Wakeham

+1 858.836.5000

investorrelations@resmed.com

Source: ResMed